Goldman Sachs Group Inc 4 D Molecular Therapeutics, Inc. Transaction History
Goldman Sachs Group Inc
- $706 Billion
- Q2 2025
A detailed history of Goldman Sachs Group Inc transactions in 4 D Molecular Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 4,159,264 shares of FDMT stock, worth $28.5 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,159,264
Previous 4,168,394
0.22%
Holding current value
$28.5 Million
Previous $13.5 Million
14.61%
% of portfolio
0.0%
Previous 0.0%
Shares
22 transactions
Others Institutions Holding FDMT
# of Institutions
124Shares Held
41.2MCall Options Held
19KPut Options Held
38.3K-
Black Rock Inc. New York, NY4.9MShares$33.6 Million0.0% of portfolio
-
Bvf Inc San Francisco, CA4.63MShares$31.8 Million0.67% of portfolio
-
Ra Capital Management, L.P. Boston, MA4.56MShares$31.3 Million0.37% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.74MShares$18.8 Million0.0% of portfolio
-
Novo Holdings Hellerup, G72MShares$13.7 Million0.65% of portfolio
About 4D Molecular Therapeutics, Inc.
- Ticker FDMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 32,382,400
- Market Cap $222M
- Description
- 4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical tr...